Disclosures: Jun Li: Nothing to Disclose, Heng Yao: Nothing to Disclose, Hui Yang: Nothing to Disclose, Suwan Sun: Nothing to Disclose, Xi Liang: Nothing to Disclose, Jing Jiang: Nothing to Disclose, Jiaojiao Xin: Nothing to Disclose, Dongyan Shi: Nothing to Disclose, Xin Chen: Nothing to Disclose 2564 DEVELOPING A MACHINE LEARNING UNIVERSAL PREDICTOR FOR LIVER FIBROSIS PROGRESSION Kirstin Peters 1 Nicholas Valle 1 Jamie Yang 2 Michelle Guan 1 Tien Dong 1 , 1 UCLA, 2 University of California, Los Angeles Background: In the United States, liver disease and transplant rates are escalating despite advancements in managing viral hepatitis, largely driven by alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), which accounted for 75% of transplants in 2022
free from heavy oils and artificial fragrances
doi: 10.1186/1746-1596-8-112 58 EssexM.Rios RodriguezV.RademacherJ.ProftF.LberU.MarkL.et al
Diabetes Care 25(12):23282334 Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M (2007) Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease
Future efforts should prioritize the accumulation of high-quality clinical evidence through innovatively designed multicenter, international collaborations to achieve broader recognition from the mainstream medical community
